Latest news with #NasdaqListingRules
Yahoo
13-06-2025
- Business
- Yahoo
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn., June 13, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 45,529 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The RSUs will vest 25% on June 20, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the employee's continued employment with Quantum-Si on such vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and a RSU agreement covering the grant. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X. View source version on Contacts Investor Contact Jeff KeyesChief Financial Officerir@ Media Contact Katherine Atkinson SVPCommercial Marketingmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Cheche Group Announces Receipt of Notification Letter from Nasdaq
BEIJING, June 10, 2025 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced that it received a notification letter, dated June 5, 2025 (the "Notification Letter "), from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the "Nasdaq"), indicating that the Company is no longer in compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules as the Company's closing bid price per Class A ordinary share, par value US$0.00001 per share, has been below US$1.00 for a period of 31 consecutive business days. The Notification Letter does not result in the immediate delisting of the Company's securities. The Company would like to clarify that the Notification Letter has no current effect on the listing or trading of the Company's securities on Nasdaq. Pursuant to Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a compliance period of 180 calendar days, or until December 2, 2025 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per Class A ordinary share is at least US$1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event that the Company does not regain compliance by December 2, 2025, subject to the determination by the staff of Nasdaq, it may be eligible for an additional 180 calendar days compliance period if it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement of the Nasdaq, and provides written notice to Nasdaq of its intention to cure for the minimum bid price requirement. The Company intends to monitor the closing bid price of its Class A ordinary shares between now and December 2, 2025, and is considering its options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. The Company is currently in compliance with all other Nasdaq continued listing standards. The Notification Letter does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements or contractual obligations. Safe Harbor Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding existing and new partnerships and customer relationships, projections, estimation, and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company's ability to scale and grow its business, the Company's advantages and expected growth, and its ability to source and retain talent, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These statements involve risks, uncertainties, and other factors that may cause the Company's actual results, levels of activity, performance, or achievements to materially differ from those expressed or implied by these forward-looking statements. Further information regarding these and other risks, uncertainties, or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this press release, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements. About Cheche Group Inc. Established in 2014 and headquartered in Beijing, China, Cheche is a leading auto insurance technology platform with a nationwide network of around 108 branches licensed to distribute insurance policies across 25 provinces, autonomous regions, and municipalities in China. Capitalizing on its leading position in auto insurance transaction services, Cheche has evolved into a comprehensive, data-driven technology platform that offers a full suite of services and products for digital insurance transactions and insurance SaaS solutions in China. Learn more at Cheche Group Inc.: IR@ Crocker 652-7185 View original content: SOURCE Cheche Group Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Sify Technologies Ltd. Announces Non-Compliance with Nasdaq Listing Requirements due to Resignation of a Director
CHENNAI, India, June 10, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Ltd. (Nasdaq: Sify) (the 'Company'), a leading integrated information communications technology (or ICT) Solutions and Services provider in India, notified the Nasdaq Stock Market ('Nasdaq') on May 21, 2025 that, consequent to the resignation of Dr. Ajay Kumar from the Company's Board of Directors (the 'Board'), the Company was in non-compliance with Nasdaq Listing Rule 5605(b)(1), requiring that the majority of the Board be composed of independent directors, and Nasdaq Listing Rule 5605(c)(2), requiring that there be at least three members of the Board's audit committee. Dr. Kumar resigned to take charge of a constitutional responsibility pursuant to the order of the Hon'ble President of India. The Company also indicated its intent to rely on the cure periods in Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4)(B). Further on June 5, 2025, the Company received a letter from the Listing Qualifications Department of Nasdaq indicating that, due to Dr. Kumar's resignation, the Company no longer complies with Nasdaq's independent director and audit committee requirements as set forth in Listing Rule 5605. The notice states that, consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4), the Company would be provided with a cure period to regain compliance. Such cure period will last until the earlier of the Company's next annual shareholders' meeting, or May 15, 2026; provided that, if the next annual shareholders' meeting is held before November 11, 2025, then the Company must evidence compliance no later than November 11, 2025. The Nasdaq notice has no immediate effect on the listing or trading of the Company's ADSs on the Nasdaq Capital Market. The Company is actively engaged in identifying and evaluating the appointment of another independent director to the Board to fill the vacancies created by Dr. Kumar's resignation and to regain compliance with the Nasdaq Listing Rules within the specified cure period. If at any time before the end of the cure period, the Company complies with the requirements, the Company must submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance with the rules. In the event the Company does not regain compliance by the end of the cure period, Nasdaq will provide notice to the Company that its ADSs will be subject to delisting. At that time, the Company may appeal the Nasdaq staff's delisting determination to a Nasdaq Hearings Panel. Safe Harbor StatementThis release contains certain 'forward-looking statements' relating to the Company and its business. These forward-looking statements are often identified by the use of forward-looking terminology such as 'expects', 'intends', 'will', or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as expected, intended or planned. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements. For a discussion of the risks associated with Sify's business, please see the discussion under the caption 'Risk Factors' in the company's Annual Report on Form 20-F for the year ended March 31, 2025, which has been filed with the United States Securities and Exchange Commission and is available by accessing the database maintained by the SEC at and Sify's other reports filed with the SEC. About Sify Technologies A multiple year award winner of the Golden Peacock from the Institute of Directors for Corporate Governance, Sify Technologies is India's most comprehensive ICT service & solution provider. With Digital and AI at the core of our solutions portfolio, Sify is focused on the changing ICT requirements of the emerging Digital economy and the resultant demands from large, mid and small-sized businesses. Sify's infrastructure comprising state-of-the-art Data Centers, the largest MPLS network, partnership with global technology majors and deep expertise in business transformation solutions modelled on the cloud, make it the first choice of start-ups, SMEs and even large Enterprises on the verge of a revamp. More than 10000 businesses across multiple verticals have taken advantage of our unassailable trinity of Data Centers, Networks and Digital services and conduct their business seamlessly from more than 1700 cities in India. Internationally, Sify has presence across North America, the United Kingdom and Singapore. Sify, Sify Technologies and are registered trademarks of Sify Technologies Limited. For further information, please contact: Sify Technologies LimitedPraveen KrishnaInvestor Relations & Public Relations+91 20:20 Media Nikhila Kesavan+91 Weber ShandwickLucia Domville+1-212 546-8260LDomville@ Sign in to access your portfolio
Yahoo
03-06-2025
- Business
- Yahoo
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Media Contact:David RosenArgot in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
31-05-2025
- Business
- Business Insider
9F Inc receives Nasdaq notification regarding late filing of Form 20-F
9F Inc (JFU). announced that it received a notification letter dated May 23, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market Inc., indicating that the company is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) since the company did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission. The Notification Letter has no immediate effect on the listing of the company's American depositary shares on Nasdaq. Pursuant to the Nasdaq Listing Rules, the company has 60 calendar days from the date of the Notification Letter to submit a plan to regain compliance with Nasdaq Listing Rules. If Nasdaq accepts the Compliance Plan, it may grant the company an extension until November 11, 2025 to regain compliance. The company expects either to file its 2024 Form 20-F or submit the Compliance Plan within the prescribed 60-day period. Confident Investing Starts Here:
